• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Open Science

The Open Science Statement of the International Alliance of ALS/MND Associations consists of Values, Principles and Practices as shown in the chart below. The practices are outlined in more detail following the chart.  Our expectation is that any Alliance research collaborators must commit to making their outputs (materials and knowledge) publicly available without restriction on use and adhere to the following values, principles and practices, which support the values of the International Alliance of ALS MND Associations with respect to Open Science.

Values, Principles and Practices

Values Principles Practices
Human-centric
  • Fairness
  • Representative
  • Respectful
  • Inclusive
  • Communications
  • Behaviours
  • PALS/CALS driven
  • Accountability
  • IP
  • Auditable
Knowledge-sharing
  • Urgency
  • Timely
  • Transparency
  • Article access
  • Interoperable
  • Data & code access
  • Replicable & reproducible
  • Protocols
Trustworthy
  • Reliability
  • Accessible documentation
  • Private & secure
  • Compliance processes & guidelines
  • Follow-on research
  • Re-use
  • Attribution & acknowledgement

Practices

  1. Each researcher or project will have a plan for how the principles of Open Science will be adhered to from inception to the end of the project. That plan will include how the values of human centric, the knowledge sharing, and the trustworthiness will be met.
  2. Where possible, existing human data will be used so PALS and CALS do not have to undergo repeat testing if they have made informed consent to make their data available under open science principles.
  3. Post experimental protocols to a protocol-sharing service, such as protocols.io
  4. All articles resulting from funding must be published in a fully open access journal or posted in an open repository with free, immediate readership rights
  5. Researchers will seek to place open access results arising from research projects (internal or collaborative) in the public domain. Researchers will not, under any Alliance Project they undertake (internal or collaborative), file any form of patent application, or allow a collaborator to restrict the research use of Open Access Project Outputs.
  6. Data will be shared according to FAIR principles [Findability, Accessibility, Interoperability, and Reuse of digital assets]
  7. Researchers will promptly release the associated output data through free and publicly accessible digital repositories while still maintaining compliance with any privacy and confidentiality regulations.
  8. Any data, code, and software needed for independent verification of research results must be curated and made free and publicly available in an established, open repository no later than the publication of the first paper based on the data, or no later than the expiration of the grant, whichever comes first.
  9. Research outputs (articles, data, code, and software) resulting from funding must be made available with generous reuse & remixing rights (e.g. CC BY.CCO licences)
  10. Applicants will be encouraged to include the anticipated costs for making their work open in their grant applications.
  11. All researchers and projects will include a data-sharing plan as part of the application process and there will be compliance checkpoints throughout the term of engagement which proactively compiles proof of policy compliance as a component of interim and final reports

Primary Sidebar

  • Laurie Petit-Jean, France

    Laurie Petit-Jean, France

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Liam Dwyer, England

    Liam Dwyer, England

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Federica Mastrosimone, Italy

    Federica Mastrosimone, Italy

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

  • Jean

    Jean
    jean

  • Lineke Veenstra, Netherlands

    Lineke Veenstra, Netherlands

  • Steven Spencer, New Zealand

    Steven Spencer, New Zealand

  • Lin Yong Yi, Taiwan

    Lin Yong Yi, Taiwan

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Jorge Luis Fernández Romero, Mexico

    Jorge Luis Fernández Romero, Mexico

  • Lee Millard, England

    Lee Millard, England

  • Magdalena Ayala Rodríguez, Mexico

    Magdalena Ayala Rodríguez, Mexico

  • Dr. Shelly Hoover, USA

    Dr. Shelly Hoover, USA

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Angie Bordaen, Belgium

    Angie Bordaen, Belgium

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Brian Parsons, Canada

    Brian Parsons, Canada

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Sharon Corosanite, USA

    Sharon Corosanite, USA

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • João Marcos Andrietta, Brazil

    João Marcos Andrietta, Brazil

  • Verónica Isabel Castro Molina, Argentina

    Verónica Isabel Castro Molina, Argentina

  • Ismail Gokcek, Turkey

    Ismail Gokcek, Turkey
    ismail_gokcek_alsmnd_tr

  • Mark Miller, UK

    Mark Miller, UK

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Eddy Lefrancois, Canada

    Eddy Lefrancois, Canada

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Ali Var, Turkey

    Ali Var, Turkey

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • John Sweeney, USA

    John Sweeney, USA

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Bob Simonds, USA

    Bob Simonds, USA

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Chih Ching Darren Wong, Malaysia

    Chih Ching Darren Wong, Malaysia

  • Imelda Arenas, Colombia

    Imelda Arenas, Colombia

  • Torben Mikkelsen, Denmark

    Torben Mikkelsen, Denmark

  • Joanne Pratt, Australia

    Joanne Pratt, Australia

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Hiroshi Matsuyama, Japan

    Hiroshi Matsuyama, Japan

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Chen Chun-Chin, Malaysia

    Chen Chun-Chin, Malaysia

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Steve

    Steve

  • Susan Anderson, USA

    Susan Anderson, USA

  • Kris Van Reusel, Belgium

    Kris Van Reusel, Belgium

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login